🔥Hot off the press: ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer ESMO Open doi.org/10.1016/j.esmo… 👉get the lastest update on the management of biliary tract cancer ESMO - Eur. Oncology EASL Education ILCA Cholangiocarcinoma Foundation #livertwitter

My plan for 2025: I will no longer review for journals that charge APCs. I can no longer tolerate this exploitation of labor. The reviewer and editor work for free, while the author pays—and someone else profits...

Pancreatic cancer, often linked to smoking, obesity and diabetes, is predicted to become the 2nd leading cause of cancer-related death by 2030. A recent Seminar discusses the need for novel therapies & future directions for research: hubs.li/Q03hN4Hj0

KEYNOTE-689 Update at #AACR25 Neoadjuvant + adjuvant #pembrolizumab in resectable LA-HNSCC ✅ EFS HR: 0.73 (95% CI 0.58–0.92) ✅ Median EFS: 51.8 mo vs 30.4 mo ✅ CPS ≥10 subgroup: HR 0.66 (95% CI 0.49–0.88) ✅ 2-yr EFS: 75% vs 62% ✅ Early & sustained KM curve separation ✅

NEWS FROM INDUSTRY: SOURCE MERCK KEYNOTE-B96 Update #OvarianCancer The Phase 3 KEYNOTE-B96 (ENGOT-ov65) trial demonstrated that pembrolizumab combined with chemotherapy (paclitaxel), with or without bevacizumab, significantly improved progression-free survival (PFS) in patients

KRYSTAL-7: Ada + Pembro, KRAS G12C NSCLC, Ph2 ✅ORR 44% ITT, 61% PD-L1 >50% ✅mPFS 11.0m ITT, 26.7m PD-L1 hi 🔹 By comparison, Pembro 7-8m, chemoIO 9m ✅mOS 18.3m, NR PD-L1 hi ❗️60% Gr3+ TRAE: GI & liver ❗️High dose redn & interr Active, AEs common, Ph3 ongoing #LCSM #ASCO25

Landmark OS data from #CheckMate816 just dropped in NEJM! 🫁 Neoadjuvant #Nivolumab + chemo in resectable #NSCLC delivers: ✅ 5-yr OS: 65.4% vs 55.0% ✅ HR: 0.72 (p=0.048) ✅ Lung cancer–specific survival HR: 0.65 ✅ OS with pCR: 95.3% ✅ ctDNA clearers: 75%+ OS 📌 No lung

From ESR1 & PIK3CA-guided therapies to novel SERDs, ADCs, and CDK2 inhibitors—treatment sequencing is evolving rapidly. ✅Precision oncology is no longer optional—it’s the standard. OncoDaily OncoAlert LARVOL ascopubs.org/doi/pdf/10.120…

📢🔵Bemarituzumab press release Phase 3 FORTITUDE-101 ➡️FGFR2b overexpressed gastric cancer ➡️First-line bemarituzumab plus chemotherapy (mFOLFOX6) vs chemo ✅ OS benefit at a pre-specified interim analysis 🚨Most common TEAE (>25%): reduced visual acuity, punctate keratitis,

Zanidatamab plus chemotherapy as first-line treatment for HER2-positive GC/GEJ cancer The Lancet Oncology doi.org/10.1016/S1470-… 🔎single-arm, phs 2 👉ORR 76·2% 👉mPFS 12·5 mo 👉mOS 36·5 mo 🧐Looks promising, now combo w/ ICI, phs-3 awaited ESMO - Eur. Oncology

Oxaliplatin in Stage II–III CRC: Age Matters 🔹 Stage III, ≤70 yrs → OS benefit 🔹 Stage III, >70 yrs → No OS gain 🔹 Stage II (any age) → No OS benefit 💬 Supports an individualized, age- and stage-adapted approach to adjuvant oxaliplatin use jamanetwork.com/journals/jaman…

Zongertinib in Previously Treated HER2-Mutant NSCLC 💥Now FDA-approved nejm.org/do/10.1056/NEJ…

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…

Deeply honored to have served as a co-chair of the Bladder Cancer Masterclass in the beautiful Brno (Czech Republic). Thank you to attendees and speakers for their engagement and collaboration, and specially to my co-chair Alexandr Poprach. Safe trips back home for everyone!

HRS-4642 combined with gemcitabine and nab-paclitaxel in KRAS-G12D PDAC #ESMO25 #ESMOAmbassadors 👉 ORR: 63%, DCR 92% 👉 6mo PFS rate: 89% 👉 manageable safety 🧐 KRASi are the future in 1L… @myesmo

GFH375 Ph I/II (mono, pretreated PDAC): ORR 41%, DCR 97%, mPFS 5.5 mo 4-mo PFS 78%, OS 92% GemNP + HRS-4642 PhI/II (1L PDAC): ORR 63%, DCR 93% 6-mo PFS 89% By comparison, NALIRIFOX in NAPOLI-3: ORR 42%, DCR 68%, 6-mo PFS ~60% Interesting data- NALIRIFOX + KRASi next? #ESMO25

🔥off the press🔥 Clinical practice & implications of biomarker testing in biliary tract cancer: an observational study JHEP Reports doi.org/10.1016/j.jhep… 🔎RWD, 1500 pts, 18 centers 👉striking differences in GA detection rate 👉we provide predictive & prognostic impact of

Scenarios that could explain these positive results: 1) giredestrant > AI even in the absence of ESR1 mutations 2) giredestrant = AI, but an improved tolerability (e.g. less arthralgias) may have improved compliance and therefore outcomes 3) both 1 and 2 are true

Press release: Zanidatamab + tislelizumab + chemotherapy→ improved significantly PFS+ OS in First-Line HER2-Positive GEA oncodaily.com/trial-updates/… ir.zymeworks.com/news-releases/…

JUST IN: EVP does it again! Positive EV-304 data (following ESMO - Eur. Oncology 2025 with EV-303 trial): EVP improves EFS and OS in in cisplatin-ELIGIBLE patients with muscle-invasive bladder cancer! pfizer.com/news/press-rel…